LI-RADS实际运用现状分析

doi:10.7517/issn.1674-0475.190804

摘要/Abstract

摘要： 肝脏影像报告和数据系统（LI-RADS）为影像诊断和术后评估提供了规范化的依据，运用影像表现特征，对高危人群的肝局灶病灶和术后细胞存活情况进行分类、评估。LI-RADS分类系统主要征象包括动脉期高强化、大小、包膜表现、廓清表现、超阈值生长，并对HCC诊断具有高度的特异性，明确存在的主要征象视为有、不明确时视为无。该系统无偿提供了一些有助于影像科医生工作的在线资源，其中有图表、专业术语、成像技术、影像报告指南以及模板等。本文介绍了LI-RADS的实际运用情况。

关键词: 肝脏, 肝细胞肝癌, 磁共振成像, 肝脏影像报告和数据系统

Abstract: Liver Imaging Reporting and Data System (LI-RADS) provides a standardized basis for image diagnosis and post-operative evaluation, and classifies and evaluates liver lesions and cell survival in high-risk population with image features. The main signs of LI-RADS classification system include arterial phase enhancement, size, capsular appearance, clearance performance, and 116 over-threshold growth. LI-RADS classification system has high specificity for HCC diagnosis. LI-RADS provides some online resources, including charts, terminology, imaging technology, image reporting guidelines and templates, which are helpful to the work of image surgeons.

Key words: liver, hepatocellular carcinoma, magnetic resonance imaging, LI-RADS

李敬伟, 王志鹏, 张鹏, 高凤国, 张鹏, 于连泽. LI-RADS实际运用现状分析[J]. 影像科学与光化学, 2020, 38(1): 116-124.

LI Jingwei, WANG Zhipeng, ZHANG Peng, GAO Fengguo, ZHANG Peng, YU Lianze. Analysis of the Actual Application of LI-RADS[J]. Imaging Science and Photochemistry, 2020, 38(1): 116-124.

参考文献

[1] Liver imaging reporting and data system (LI-RADS)[S]. ACR website.
[2] Cruite I, Tang A, Sirlin C B. Imaging-based diagnostic systems for hepatocellular carcinoma[J]. American Journal of Roentgenology, 2013, 201:41-55.
[3] Welzel T M, Graubard B I, El-Serag H B, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States:a population-based case-control study[J].Clinical Gastroenterology and Hepatology, 2007, 5:1221-1228.
[4] Shropshire E L, Chaudhry M, Miller C M, et al. LI-RADS treatment response algorithm:performance and diagnostic accuracy[J]. Radiology, Published online April 30, 2019.
[5] Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma:an update[J]. Hepatology, 2011, 53:1020-1022.
[6] Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis:prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma[J]. Hepatology, 2008, 47:97-104.
[7] Efremidis S C, Hytiroglou P. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation[J]. European Radiology, 2002, 12:753-764.
[8] Theise N D, Curado M P, Franceschi S, et al. Hepatocellular Carcinoma. WHO Classification of Tumours of the Digestive System[M].International Agency for Research on Cancer (IARC), 2010.205-216.
[9] Choi J W, Lee J M, Kim S J, et al. Hepatocellular carcinoma:imaging patterns on gadoxetic acidenhanced MR images and their value as an imaging biomarker[J]. Radiology, 2013, 267(3):776-786.
[10] Marrero J A, Hussain H K, Nghiem H V, et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass[J]. Liver Transpl,2005, 11:281-289.
[11] Lee J M, Choi B I. Hepatocellular nodules in liver cirrhosis:MR evaluation[J]. Abdom Imaging,2011, 36:282-289.
[12] Cruite I, Schroeder M, Merkle E M, et al. Gadoxetate disodium-enhanced MRI of the liver:part 2, protocol optimization and lesion appearance in the cirrhotic liver[J].American Journal of Roentgenology, 2010, 195:29-41.
[13] Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma:usefulness of gadoxetic acid-enhanced MR imaging[J]. Radiology, 2011, 261:834-844.
[14] Sangiovanni A, Manini M A, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis[J]. Gut, 2010, 59:638-644.
[15] Llovet J M, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis[J]. Gastroenterology, 2006, 131:1758-1767.
[16] Yoshioka H, Takahashi N, Yamaguchi M, et al.Double arterial phase dynamic MRI with sensitivity encoding (SENSE) for hypervascular hepatocellular carcinomas[J]. Journal of Magnetic Resonance Imaging, 2002, 16:259-266.
[17] 邢古生. 肝细胞肝癌的CT及MR比较影像学分析[D].北京:中国协和医科大学, 2009. Xing G S. CT and MR imaging analysis for hepatocellular carcinoma[D].Beijing:Peking Union Medical College, 2009.
[18] Ichikawa T, Kitamura T, Nakajima H, et al. Hypervascular hepatocellular carcinoma:can double arterial phase imaging with multidetector CT improve tumor depiction in the cirrhotic liver[J].American Journal of Roentgenology, 2002, 179:751-758.
[19] Takahashi N, Yoshioka H, Yamaguchi M, et al. Accelerated dynamic MR imaging with a parallel imaging technique for hypervascular hepatocellular carcinomas:usefulness of a test bolus in examination and subtraction imaging[J]. Journal of Magnetic Resonance Imaging,2003,18:80-89.
[20] Yuki K, Hirohashi S, Sakamoto M, et al. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases[J]. Cancer, 1990, 66:2174-2179.
[21] Van Den Bos I C, Hussain S M, Dwarkasing R S, et al.MR imaging of hepatocellular carcinoma:relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns[J]. Journal of Magnetic Resonance Imaging, 2007, 26:1548-1555.
[22] Pawlik T M, Delman K A, Vauthey J N, et al. Tumor size predicts vascular invasion and histologic grade:implications for selection of surgical treatment for hepatocellular carcinoma[J]. Liver Transpl, 2005, 11:1086-1092.
[23] Suh Y J, Kim M J, Choi J Y, et al. Differentiation of hepatic hyperintense lesions seen on gadoxetic acidenhanced hepatobiliary phase MRI[J].American Journal of Roentgenology, 2011, 197:44-52.
[24] Kitao A, Zen Y, Matsui O, et al. Hepatocarcinogenesis:multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography-radiologic-pathologic correlation[J]. Radiology, 2009, 252:605-614.
[25] Yu J S, Rofsky N M. Magnetic resonance imaging of arterioportal shunts in the liver[J]. Topics in Magnetic Resonance Imaging, 2002, 13:165-176.
[26] Pomfret E A, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States[J].Liver Transpl, 2010, 16:262-278.
[27] Ishigami K, Yoshimitsu K, Nishihara Y, et al. Hepatocellular carcinoma with a pseudocapsule on gadoliniumenhanced MR images:correlationwith histopathologic findings[J]. Radiology, 2009, 250:435-443.
[28] Valls C, Cos M, Figueras J, et al. Pretransplantation diagnosis and staging of hepatocellular carcinoma in patients with cirrhosis:value of dual-phase helical CT[J].American Journal of Roentgenology, 2004, 182:1011-1017.